Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-01-23

Clinical Trial Update: Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants [Phase 4]

View source ↗

Summary

Phase 4 trial comparing FK506 (advagraf) drug levels between First Nations and Caucasian liver transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Advagraf (tacrolimus)

Snippet

Sponsor: University of Manitoba | Conditions: Liver Failure | Phase 4 | Status: COMPLETED